Share

April 13, 2021; 96 (15 Supplement) Saturday, April 17

Cases of COVID-19 in Alemtuzumab-Treated Patients With MS: Pharmacovigilance Report (2059)

Gavin Giovannoni, Aaron L. Boster, Regina Berkovich, Krzysztof W. Selmaj, Luke Chung, Debora Shiota, Salman Afsar
First published April 13, 2021,
Citation
Permissions

Make Comment

See Comments

Downloads
0

Share

Article Information

vol. 96 no. 15 Supplement 2059
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
0028-3878
Online ISSN: 
1526-632X
History: 
  • First Published April 13, 2021.
Copyright & Usage: 
© 2021

Author Disclosures

    1. Gavin Giovannoni1,
    2. Aaron L. Boster2,
    3. Regina Berkovich3,4,
    4. Krzysztof W. Selmaj5,
    5. Luke Chung6,
    6. Debora Shiota6 and
    7. Salman Afsar6
  1. Gavin Giovannoni1,
  2. Aaron L. Boster2,
  3. Regina Berkovich3,4,
  4. Krzysztof W. Selmaj5,
  5. Luke Chung6,
  6. Debora Shiota6 and
  7. Salman Afsar6
  1. 1Queen Mary University of London, Barts and The London School of Medicine
  2. 2Boster MS Center
  3. 3Regina Berkovich, MD, PhD, Inc
  4. 4Keck School of Medicine of University of Southern California
  5. 5Department of Neurology, University of Warmia and Mazury
  6. 6Sanofi

Article usage

Article usage: April 2021 to January 2023

AbstractFullPdfSource
Apr 20211000Highwire
May 20212100Highwire
Jun 2021700Highwire
Jul 2021700Highwire
Aug 20215700Highwire
Sep 20212200Highwire
Oct 20211000Highwire
Nov 20211200Highwire
Dec 20211400Highwire
Jan 20222300Highwire
Feb 20221300Highwire
Mar 20223000Highwire
Apr 20221100Highwire
May 2022600Highwire
Jun 2022600Highwire
Jul 20221800Highwire
Aug 2022900Highwire
Sep 2022800Highwire
Oct 2022100Highwire
Nov 2022300Highwire
Dec 2022200Highwire
Jan 2023100Highwire

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

  • No related articles found.

Alert Me